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Abstract: Background: The treatment of unicompartmental arthritis in younger patients is challenging. The aim of this 
study is to report final safety and efficacy analysis results for the iForma patient–specific interpositional device, which is 
designed for the treatment of isolated medial or lateral compartment arthritis of the knee. 
Methods: From June 2005 to June 2008 78 subjects (42 men, 36 women) received an iForma implant. The mean age was 
53 years, the mean Body Mass Index 29.0. We surveyed the WOMAC scores, the visual analog pain scale and the Knee 
Society Scores. 
Results: The mean follow up was 16.4 months. The mean WOMAC knee scores increased from 48.3 before surgery to 
71.3 after 24 months. A reduction in pain was achieved for all five pain measures using a standard visual analog scale 
(VAS). Knee Society Knee Score improved from 39.2 before to 61.9 24 month after surgery. The Knee Society Function 
Scores improved form preoperative 64.5 to 82.5 2 years postoperative. The preoperative range of motion could be 
restored. The overall revision rate was 24%. 15 implants were removed early, 4 knees were revised without implant 
removal. 
Conclusion: Within narrow indication of patients with unicompartmental disease, the iForma device can provide 
improvement in knee function and reduction in pain, however, with a significant higher risk of early revision compared to 
traditional arthroplasty. Respecting this limitation it may be an alternative option for arthritic patients with 
unicompartmental disease who have contraindications to High Tibial Osteotomy or are too young for knee replacement; 
the iForma device further has the distinct advantage of time and cost saving compared to those procedures. 
Keywords: Unicompartmental knee arthritis, Hemiarthroplasty, Interpositional implant, patient-specific. 
INTRODUCTION 
  Orthopedic surgeons see increasing numbers of younger 
(i.e. <60 years), more active patients with unicompartmental 
osteoarthritis of the knee. These patients have passed the age 
for biological cartilage repair, but are considered too young 
for traditional, more invasive joint replacement. A typical 
patient profile includes those who have undergone one or 
more arthroscopies for mechanical symptoms of the knee 
and who suffer from recurrent pain related to cartilage loss 
and early osteoarthritis. The treatment of middle-aged, active 
patients, however, is challenging
  [1]. For patients who 
continue to have disabling pain and interference with daily 
activities in spite of conservative treatment, a less invasive 
surgical intervention may be indicated. Micro-fracture is 
generally not recommended in patients over 40 years of age 
[2, 3]. HTO can correct malalignment, but it involves a 
highly invasive surgical procedure that may pose problems 
during later knee replacement [4, 5]. Arthroplasty provides 
good pain relief for most patients, either total-knee 
arthroplasty (TKA) or unicompartmental knee arthroplasty 
(UKA). Both, however, require significant bone resection. 
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  For patients with osteoarthritis limited to a single 
femoral-tibial compartment, the concept of a metallic-
hemiarthroplasty has a long history. Having been introduced 
in the 1950’s by MacIntosh and McKeever
  [6, 7], the 
approach gained only limited use within the orthopedic 
community due to its invasive nature and the advent of total 
knee replacement. Nonetheless, the reports of early 
experience with this technique were generally encouraging
 
[6, 7]. More recent clinical reports by Scott and colleagues
 
[8] and Emerson and Potter
 [9] also reported good results. 
The most recent report of long-term results, published by 
Springer, Scott and colleagues in 2006
  [10] continued to 
show excellent long-term results with tibial hemiarthroplasty 
using the McKeever device. However, contrary outcomes 
have been reported with the Unispacer™ knee system 
(Zimmer, Warsaw, IN, USA) with, in some studies, high 
failure rates at 6 months and after, ranging between 16 and 
44 percent t
 [11-14]. 
  In contrast to the Unispacer, the iForma is a patient–
specific interpositional device. The undersurface of the 
implant replicates the tibial articular surface resulting in 
functional fixation similar to a McKeever device. The top 
surface conforms to the shape of the femoral condyle (Fig. 
1). The implant is developed from a standard MRI scan 
using a novel image-to-implant technology that converts the 
topography of the patient’s articular cartilage and 38    The Open Orthopaedics Journal, 2011, Volume 5  Koeck et al. 
subchondral bone to a patient-specific implant. Goal of the 
present study was to find out, whether an individualized 
interpositional device is a valuable option for treatment of 
unicompartmental knee arthritis. We evaluated the safety and 
clinical efficacy of the iForma implant in a single-arm multi-
center study in the United States and Europe in 78 patients. 
Western Ontario MacMaster (WOMAC) scores [15, 16], 
Visual Analog Scale (VAS) of pain [17, 18] and the Knee 
Society Scores [19] were measured at different time intervals 
over a 2-year period. 
MATERIALS AND METHODS 
Subjects 
  The prospective single-arm, multi-center study was 
reviewed and approved by a central Institutional Review 
Board in the United States and local ethics commissions in 
Europe (IRB No. 04/75, Regensburg University) in 2004. 
Before being enrolled in the study, all subjects gave written 
informed consent to participate. During the period from June 
2005 through June 2008, 78 subjects were enrolled at four 
sites in the USA and five sites in Germany. At each site one 
single surgeon, who had successfully completed bioskills 
training and had implanted at least three iForma 
interpositional devices, determined the indication and 
performed the procedures. Indications, contraindications, as 
well as inclusion and exclusion criteria used for trial 
enrollment, are shown in Table 1. 
  Data was collected at each site according to the schedule 
of assessment in Table 2, and documented on paper Case 
Report Forms (CRFs). Various assessment tools were   
 
employed in this study to assess the pain and function after 
surgery. 
  The WOMAC knee index [15] is a patient-administered 
questionnaire which assesses three dimensions of pain, 
disability and joint stiffness. We used the reduced WOMAC 
function scale which transforms the raw WOMAC function 
score to a 0 to 100 scale, worst to best. A score of 0 indicates 
extreme restriction in all activities, and a score of 100 
indicates no restriction for any item [16]. 
  The Knee Society rating system (KSS) [19] is a 
commonly used tool which combines a knee score that rates 
the knee joint only and functional score that rates the 
subject's ability to walk and climb stairs. The KSS Knee 
Score and Function Score range from 0 to 100 with 0 being 
worst and 100 being best. 
  Subjects were examined and questioned regarding the 
occurrence of adverse events at each follow-up visit. 
  In addition to routine radiographic images, pre-operative 
MRI scans were acquired using a protocol consisting of 
coronal and sagittal cartilage-sensitive pulse sequences with 
3.5mm slice-thickness. MR images were evaluated by the 
surgeon and an independent radiologist delegated by the 
manufacturer. The MRI scans and the radiologist analysis 
were also used to assess each subject for indications and 
contraindications as specified in Table 1. An individualized 
medial (Fig. 1) or lateral interpositional implant was 
constructed based on the patient’s MRI by ConforMIS, Inc., 
(Burlington, MA 01803) using proprietary image-to-implant 
software and then manufactured using a CAD/CAM process. 
Table 1.  Indications/Inclusion Criteria and Contraindications/Exclusion Criteria 
 
Indications/Inclusion Criteria  Contraindications/Exclusion Criteria 
•  Isolated medial or lateral osteoarthritis of the knee 
•  Cartilage damage in opposite compartment grades 0, I or II, asymptomatic 
•  Cartilage damage in the patellar-femoral compartment grades 0, I or II, 
asymptomatic 
•  Age between 35 and 65 years 
•  Intact subchondral bone plate 
•  Severe patellofemoral or tibiofemoral osteoarthritis in the 
opposite compartment > grade III 
•  Severe articular instability caused by loss of osteochondral 
structures, e.g. femoral flattening 
•  Ligament instability or loss of collateral or cruciate ligament 
integrityFlexion contracture > 15 deg. 
•  Generalized bone disease, including osteoporosis, Paget’s disease 
or other metabolically induced bone disease 
•  Presence of active infection 
 
Table 2.  Visit Schedule of Assessments 
 
Visit  Pain (VAS)  Medication  Knee Society Health Survey  Knee Evaluation  X-Ray  Operative Data  WOMAC Survey 
Pre-op X  X  X  X  X    X 
Intra-op         X  X   
Discharge X  X    X       
6 Weeks  X  X  X  X       
3 months  X  X  X  X  X     
6 months  X  X  X  X  X    X 
12 months  X  X  X  X  X    X 
24 months  X  X  X  X  X    X Patient-Specific Interpositional Knee Implant  The Open Orthopaedics Journal, 2011, Volume 5    39 
 
Fig. (1). Patient specific interpositional device. 
Surgical Technique and Post-Operative Care 
  In all cases, as the first step of a one-stage-prodedure, an 
arthroscopic resection of the posterior horn of the meniscus, 
leaving a 2 mm narrow seam, was performed. The compart-
ment was opened with a medial or lateral parapatellar 
incision using a minimally invasive technique. The anterior 
horn of the meniscus was mobilized and completely removed 
up to the dorsal resection boundary with the menisectomy 
ensuring the preservation of capsular as well as further soft 
tissue integrity. With a Luer rasp and a small file, any 
existing peripheral femoral and tibial osteophytes were 
removed. Following that, the device was inserted using a 
grasper (Fig. 2). 
 
Fig. (2). Interpositional device being inserted using the grasper. 
  Medial implants were inserted starting from a 45° flexed 
position with valgus stress applied to the knee joint from 
antero-medial to dorso-lateral using a slight tilting motion. 
Lateral implants were inserted starting with a 45° tilt of the 
implant strictly from lateral to medial with simultaneous 
varus stress applied. Implant stability and range of motion 
were verified visually, by palpation, and by dynamic 
fluoroscopy (Fig. 3). 
  Closure of the wound was performed in several layers 
using standard technique. Drains were placed at the 
discretion of the individual surgeon. 
  Subjects were discharged with instructions for pain 
management during the first 2 days in the US and 5 days in 
Germany, including the use of ice, NSAIDs or prescribed 
pain medication. Limited activity was permitted upon 
discharge, with weight bearing permitted as tolerated. 
Passive motion was not used postoperatively. Physical 
therapy or directed activity was recommended according to 
the individual surgeon’s preference. Usually no post-
operative bracing was used. 
 
Fig. (3). Fluoroscopy of interpositional device placement and range 
of motion. 
Statistical Methods 
  All data related to the study was summarized using 
standard descriptive statistics. The analysis of variance 
(ANOVA) methods for repeated measurements and Tukey’s 
multiple comparison tests as a post-hoc analysis were used 
for comparing means of WOMAC and VAS scores for all 
patient visits. Estimates of mean differences and their 95% 
confidence intervals were presented. The study hypotheses 
were tested on the level of alpha = 5% throughout the 
analysis. Bonferroni adjustments were made for multiple 
comparisons. All statistical analyses comparing mean scores 
for all visits were performed using SAS statistical software, 
version 9.1 (SAS Institute, Cary, NC, U.S.A.) and graphs 
were plotted using R-software (The R-Foundation for 
Statistical Computing). 
RESULTS 
  At the time the study was voluntarily terminated 
(September 2009), 78, 73, 72, 58, 44, and 26 patients had 
completed their visits at the preoperative, 1 month, 3 month, 
6 month, 12 month and 24 month follow-up intervals, 
respectively (Table 3). 
  The mean follow up was 16.4 months. Of the 78 
implants, 72 (92%) were medial, and 6 (8%) lateral. The 
mean age at the time of surgery was 53 years (range 37-71 
years; 1 subject was entered outside the specified range as a 
protocol exception). The mean BMI was 29.0 (14.7 to 43.3, 
SD 5.47); 52% of patients were male, 48% of the patients 
were female. All patients had arthroscopy before the 
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was rated grade III in 22%, and grade IV in 74% of the 
affected compartments. 
  The mean WOMAC-Score increased from 48.3 before 
surgery to 68.9 at 6 months. Improvement in the reduced 
WOMAC score at 6 months remained consistent and 
statistically significant through 24 months (Table 4). 
  The Knee Society Knee Scores increased steadily after 
surgery through the 24 month follow-up visit, with the 
largest increase of 22% occurring between the pre-operative 
and the 1 month/6 week follow-up visit (p<0.05) (Table 4). 
  The Knee Society Function Scores (subject's ability to 
walk and climb stairs) demonstrated a decrease immediately 
after the implant surgery at the 1 month/6 week follow-up 
visit due to the recovery period from the surgery. However, 
the Knee Society Function scores steadily increased after the 
1 month/6 week follow-up visit through 24 month follow-up. 
By 24 months, the mean Knee Society Function Score had 
increased by 28% when compared to the pre-operative mean 
Knee Society Function Score (p<0.05). The mean Knee 
Society Function Score demonstrated an improvement in the 
subject’s ability to participate in various activities (Table 4) 
as well as an improvement in subject’s ability to walk 
without supportive devices (Table 4). At baseline, 62% of 
the subjects reported only being capable of minimal walking 
or light housework/office work and 76% of subjects were 
able to walk only up to one hour without supportive devices. 
By their 24 month follow-up visit, 92% of the subjects 
reported being able to do at heavy housework/light exercise 
or moderate to vigorous sports and 69% of the subjects were 
able to walk for over one hour without supportive devices 
(Table 4). 
  Statistically significant reduction in pain as measured by 
the WOMAC Pain Scores was achieved for all five pain 
measures following the procedure (p<0.05). Pain decreased 
steadily, immediately following the surgery as demonstrated 
by VAS scores at discharge, and continued to decrease 
through the 24 month follow-up visit (Fig. 4). 
  The only exception was for the activity of “standing” - 
the VAS score demonstrated a slight increase from 2.1 at the 
12 month follow-up visit to 2.3 at the 24 month follow-up 
visit. The greatest improvements in pain were seen between 
the pre-op and discharge visits which may be related directly 
to the surgical implant of the interpositional device, and 
between the 3 month and 6 month visits which may be 
related to the time needed by the subjects to fully recover 
from the surgery. Remarkably, VAS pain scores decreased 
significantly (p<0.05) from the preoperative level at the time 
of discharge for the three active state evaluations (walking, 
standing upright and walking down stairs). Pain while sitting 
or lying down was significantly improved by 1 month and 
pain in bed at night achieved significant improvement by 3 
months. Pain improvement was maintained over the course 
of the study with no statistically significant difference in 
VAS pain scores between the 3, 6, 12 and 24 month 
intervals. 
  While subjects demonstrated an expected decrease in 
range of motion immediately after surgery and during their 
recovery period, on average the subjects were able to return 
to their pre-op range of motion by their 12 month follow-up 
visit. The preoperative slight mean flexion contracture of 
0.1° (SD 3.67) increased to a maximum of 2.0° (SD 17.45) at 
6 months postoperative, came back to 0.2° (SD 2.42) at 12 
months and stayed at the same level (0.2°, SD 3.53) until 24 
months. The maximum knee flexion of preoperative 129.5° 
(SD 20.43) decreased to 84.6° at the time of discharge and 
steadily increased to 120.9° (SD 22.66) at 6 months, 128.7° 
(SD 13.57) at 12 months and 130.9° (SD 16.56) at 24 months 
postoperative. 
  Of the 78 patients, there were 15 (19%) explants and 4 
(5%) surgical interventions without implant removal. These 
surgical interventions included re-arthroscopies for pain, 
Table 3.  Example of MRI Protocol Used for Generating Patient-Specific iForma Implant Design Using 1.5 Tesla Magnets 
 
Images Acquired     Plane  Pulse Sequence  TR  TE  Slice Thickness  Spacing  Matrix  FOV  Voxel Size 
Required 1  Sagittal  Proton Density FS  ~4500  ~15msec  3mm  0.5  512 X 256  14-16cm ~.27mm 
Required 2  Coronal  Proton Density FS  ~4500  ~15msec  3mm  0.5  512 X 256  14-16cm ~.27mm 
Alternative 3  Sagittal  3D- SPGR FS  ~60  ~5msec  3mm  0.5  512 X 192  14-16cm ~.27mm 
Alternative 3  Coronal  3D-SPGR FS  ~60  ~5msec  3mm  0.5  512 X 192  14-16cm ~.27mm 
Table 4.  Mean WOMAC Scores, Knee Society Knee/Function Scores and Subjects’ Ability to Walk 
 
  Preop. (n=78)  1 Month (n=74)  3 Month (n=71)  6 Month (n=58)  12 Month (n=45)  24 Month (n=26)  p-Value 
WOMAC Scores  48.3 ± 17.5  -  -  68.9 ± 18.5  70.0 ± 20.2  71.3 ± 20.0  < 0.05 
Knee Society -  
Knee Score 
39.2 ± 10.8  48.0 ± 11.6  53.1 ± 14.6  57.9 ± 15.0  59.5 ± 16.1  61.7 ± 14.7  < 0.05 
Knee Society - 
Function Score 
64.5 ± 17.8  41.2 ± 25.8  60.9 ± 23.1  72.7 ± 18.8  75.6 ± 20.3  82.5 ± 15.8  < 0.05 
Subject able to walk 
 >1h without  
supportive devices 
24% 8%  30% 41%  60%  69% - 
Values are shown as mean ± SD. Patient-Specific Interpositional Knee Implant  The Open Orthopaedics Journal, 2011, Volume 5    41 
instability or dislocation. The total revision rate of 24% is 
determined by combining the explants and surgical inter-
ventions. See Table 5 for a summary of the events leading to 
explants and surgical interventions. 
Table 5.  Number of Explants and Surgical Interventions 
 
Adverse Event  No. of  
Occurences  Explant  Surgical  
Intervention 
Persistent pain  9  7  2 
Subluxation 2  2  - 
Dislocation 3  2  1 
Instability 1  1  1 
Limp 1  1  - 
Implant impingement  1  1  - 
Infection 1  1  - 
Allergy concern  1  1  - 
Total 19  15  4 
 
DISCUSSION 
  Clinical results with unicompartmental arthroplasty have 
generally been reported to be good. Cartier and Cheaib [21] 
reported two decades ago on a series of 159 Mod U 
unicompartmental arthroplasties with a mean follow-up of 
54 months with 91% excellent clinical results and 6% 
failures. In a more recent study, Furnes and colleagues 
evaluated failure and survival rates for unicompartmental 
and total knee implants based on a decade of data in the 
Norwegian Arthroplasty records [22]. The authors found that 
unicompartmental devices had an approximate incidence of 
failure of 3% in the first year and 6% after two years. 
  The experience with the Unispacer device, however, has 
been quite different. Clinically high dislocation rates have 
been reported in the literature at time intervals as early as 6 
months after surgery [11, 12]. The unispacer represented a 
new concept of a free floating interpositional metallic 
implant that actively translates in anteroposterior direction 
and rotates with knee flexion and extension. The reported 
failure rates have resulted in limited, if any, use of the device 
today [11]. 
  The principle of functional implant stabilization of the 
iForma device which is matching the individual joint surface 
however is more similar to the principle of fixed tibial 
hemiarthroplasty using the concepts first described by 
Macintosh and McKeever [6, 7]. Scott [8] and Springer [10] 
published good long-term results with the McKeever device, 
within a narrow, well-defined indication of patients with 
unicompartmental disease and intact ligaments. 
 
Fig. (4). Mean WOMAC Pain Scores for various activities. 
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  The incidence of implant revision with the iForma in this 
study was 24%, primarily due to persistent pain and implant 
subluxation/dislocation. This failure rate is above revision 
rates for traditional unicompartmental arthroplasty [21, 22]. 
But unlike traditional arthroplasty failure modes with bone 
loss, osteolysis and implant loosening, failure of the iForma 
implant is different. The device can simply be removed. 
Since no bone or cartilage has been resected, the patient can 
still go on to UKA or primary TKA. 
  As shown in Table 3, there was a significant difference 
between complication rates of experienced surgeons who 
performed more than 10 iForma -implantations and inexperi-
enced surgeons who did fewer than 10 implantations. 
Whereas the experienced surgeons had an overall revision 
rate (Termination early due to adverse event) of 16%, the 
inexperienced surgeons had a revision rate almost three 
times higher (45%). Similar effects were shown by Hallock 
et al. for the Unispacer [13, 14], who found a marked 
decrease in complication rates between a first group of 79 
and a second group of 78 patients, and also in follow-up 
studies on UKA [23, 24]. 
  The rates of revision for pain and revision for subluxat-
ion/dislocation observed in the present study are comparable 
to the reported overall one-year revision rate of 21% for the 
Unispacer in an early report [13] but lower than the number 
of 32% reported in two-year follow-up [14]. In the second 
published report the incidence of revision for the Unispacer 
for dislocations was 16% [14], compared with 4.8% for all 
cases (including improper surgical technique) in the current 
study, and 16% for persistent pain, compared with 2.4% for 
the iForma implant in the current study. In addition, the 
implant design of the Unispacer was intended only for use in 
the medial compartment [13]. In contrast, the iForma makes 
use of functional fixation and therefore can be used for either 
the medial or lateral compartment. 
  Patients reported a rapid partial recovery, followed by 4-
8 weeks or more of continued recovery with full benefit 
typically seen at 3 months. Joint effusions were observed 
between 4 and 8 weeks after surgery, and typically resolved 
3 months postoperatively. The improvement in WOMAC 
scores compares favorably with the improvement seen in 
subjects who receive a fixed-bearing or mobile-bearing 
unicompartmental arthroplasty [25] or TKA
  [26]. Subjects 
with the iForma tend to experience a “wear-in” period lasting 
3 months which is followed by a return to full pre-operative 
range of motion within 6 months to 1 year and a continued 
trend of improved pain relief out to 2 years. 
  Limitations of the study are the lack of a control group, 
the just short- to medium-term follow-up and the 
involvement of many centers with just few implantations 
each which. The latter might have influenced the overall 
relatively high rate of failures, possibly depicting a learning 
curve and further highlighting the careful patient selection. 
However, although we can only report preliminary results 
with 2 years of follow-up, we consider the iForma to offer a 
potentially valuable option to younger subjects who may not 
be candidates for a HTO or more invasive arthroplasty 
options, such as a UKA or TKA. The device should only be 
used in patients with unicompartmental disease, who have 
intact ligaments, an intact subchondral bone plate on both the 
femur and tibia and who suffer from an intra-articular knee 
deformity, which reliably can be corrected with this implant 
as already shown [27]. 
  During the period of the study, the cost of the iForma 
implant in the US and in Germany was similar to the cost of 
a standard unicompartmental implant, although variations in 
price of competing systems at each institution varied. Taking 
into account that the time of surgery for the iForma was 
significantly lower and the cost for instrumentation and 
sterilization of the instruments was minimal compared to a 
conventional UKA or TKA, we consider it to be a 
comparable to the cost of other implant options. 
CONCLUSION 
  The preliminary two-year results of the iForma implant 
in this single-arm, multi-center trial are demonstrating 
improvement in both knee function and pain relief in a 
population that was significantly younger than typical 
candidates for UKA or TKA. However, the relatively high 
failure rate highlights careful patient selection. 
  Within a narrow, well-defined indication, in our opinion 
the iForma offers a potentially valuable option to patients 
who are border candidates for more invasive arthroplasty 
options or a HTO. A key benefit of the iForma device over 
traditional unicompartmental arthroplasty systems is the 
preservation of cartilage and bone. When the iForma device 
fails, it can be simply extracted. 
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